Skip to content
Disclosery

Saturn V Capital Management LP

Follow

13F filer, CIK 1964437, AUSTIN, TX

Saturn V Capital Management LP reported $552,217,513 across 21 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 77.03% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001964437-26-000005

Period
2026-03-31
Reported value
$552M
Holdings
21
Top 10 weight
77.03%
New
4
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CADLnew+2,896,588$14.2M
IRONadded+151,497$9.69M
IMMXadded+694,416$6.33M
ZURAnew+739,960$4.4M
IVVDadded+3,213,698$4.18M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
COGTreduced-590,429-$22.7M
OCULexited-1,504,880-$18.3M
JAZZreduced-85,109-$16.1M
DYNreduced-822,007-$14.9M
ABVXreduced-106,483-$11.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001964437-26-000005, largest first. % of portfolio is the value over $552,217,513, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,135,953 shares; 2026Q1: 3,202,075 shares 3,202,075$70.5M12.77%+66,122Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 889,073 shares; 2025Q1: 2,426,436 shares; 2025Q2: 3,260,570 shares; 2025Q3: 4,604,878 shares; 2025Q4: 4,496,487 shares; 2026Q1: 4,349,885 shares 4,349,885$60.5M10.95%-146,602Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 648,019 shares; 2024Q4: 653,071 shares; 2025Q1: 552,926 shares; 2025Q2: 622,479 shares; 2025Q3: 801,224 shares; 2025Q4: 649,179 shares; 2026Q1: 542,696 shares 542,696$60.4M10.94%-106,483Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 204,987 shares; 2024Q4: 204,285 shares; 2025Q1: 232,295 shares; 2025Q2: 544,221 shares; 2025Q3: 788,441 shares; 2025Q4: 798,940 shares; 2026Q1: 824,532 shares 824,532$47.9M8.68%+25,592Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 886,332 shares; 2025Q4: 1,140,033 shares; 2026Q1: 1,201,402 shares 1,201,402$33.9M6.15%+61,369Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,999,169 shares; 2026Q1: 3,693,585 shares 3,693,585$33.6M6.09%+694,416Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 946,335 shares; 2024Q4: 1,063,783 shares; 2025Q1: 1,093,677 shares; 2025Q2: 1,185,520 shares; 2025Q3: 473,828 shares; 2025Q4: 317,095 shares; 2026Q1: 281,904 shares 281,904$32.2M5.83%-35,191Timeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 206,952 shares; 2025Q3: 300,610 shares; 2025Q4: 248,070 shares; 2026Q1: 162,961 shares 162,961$30.8M5.58%-85,109Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 511,041 shares; 2024Q4: 509,406 shares; 2025Q1: 518,177 shares; 2025Q2: 396,115 shares; 2025Q3: 340,897 shares; 2025Q4: 298,429 shares; 2026Q1: 449,926 shares 449,926$28.8M5.21%+151,497Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 5,800,530 shares; 2026Q1: 6,456,646 shares 6,456,646$26.7M4.83%+656,116Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,712,899 shares; 2024Q4: 1,498,425 shares; 2025Q1: 1,480,020 shares; 2025Q2: 2,297,524 shares; 2025Q3: 2,025,041 shares; 2025Q4: 1,217,064 shares; 2026Q1: 626,635 shares 626,635$24.1M4.37%-590,429Timeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,370 shares; 2025Q4: 325,701 shares; 2026Q1: 345,626 shares 345,626$18.9M3.43%+19,925Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,455,429 shares; 2025Q3: 2,674,469 shares; 2025Q4: 1,788,616 shares; 2026Q1: 966,609 shares 966,609$17.5M3.17%-822,007Timeline
IVVDINVIVYD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 7,735,386 shares; 2026Q1: 10,949,084 shares 10,949,084$14.2M2.58%+3,213,698Timeline
CADLCANDEL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,896,588 shares 2,896,588$14.2M2.57%newTimeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 516,761 shares; 2026Q1: 516,761 shares 516,761$13.7M2.49%0Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,500,000 shares; 2026Q1: 4,166,666 shares 4,166,666$9.25M1.68%+1,666,666Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,856,799 shares; 2026Q1: 3,863,445 shares 3,863,445$6.49M1.18%+6,646Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 739,960 shares 739,960$4.4M0.8%newTimeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 88,999 shares 88,999$2M0.36%newTimeline
MSLESATELLOS BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares 350,000$1.97M0.36%newTimeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
OCULOCULAR THERAPEUTIX INC1,504,880$18.3Mshares
CNTACENTESSA PHARMACEUTICALS PLC282,692$7.07Mshares
IVAINVENTIVA SA283,166$1.32Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001964437-26-000005 base2026-05-15acceptance time not in the bulk data set